Teva octreotide for injectable suspension recalled
Official notice
13 Jan 2026
Last checked
13 Jan 2026
An official Health Canada notice concerns Teva octreotide for injectable suspension recalled. Teva Canada Limited is recalling all strengths (lots listed above) of the prescription drug Octreotide as a precautionary measure due to deficiencies in Good Manufacturing Practices (GMP) identified at its foreign manufacturing site. GMPs ensure drugs meet the appropriate quality standards for their intended use before they are sold. The deficiencies identified could lead to potential quality issues with the products, including microbiological contamination (leading to compromised sterility), contamination with foreign particles and concerns related to dosing accuracy. Potential serious health risks associated with these deficiencies include: Skin and muscle infections at the injection site, including cellulitis or abscess Severe blood infection Blood clots Hypersensitivity reactions, including life threatening allergic reactions Inflammatory reactions/lumps at the injection site Lack of therapeutic effect due to an insufficient dose Symptoms of overdose, such as hot flushes, frequent urination, fatigue, depression, anxiety and lack of concentration, or worsened side effects. Teva Octreotide acetate for injectable suspension is a long-acting prescription medication used to treat certain hormone-related disorders, including acromegaly (a condition caused by too much growth hormone), as well as severe diarrhea and flushing caused by certain tumors. Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventive actions. The Department will inform the public if any new health risks are identified. Published 2026-01-13.
What to do now
If you have an affected product, do not use it. Speak to your health care professional immediately to obtain an alternative or replacement product. If you are unsure whether your product is affected, check with your pharmacy. Seek medical attention if you have used this product and are experiencing symptoms of infection, or other unexpected symptoms or side effects. Return affected product(s) to the pharmacy where it was purchased for proper disposal. Consult a health care professional if you have used the affected product and have health concerns. Contact Teva Canada Limited by calling toll-free at 1-800-268-4127, option 3, or by email at druginfo@tevacanada.com, if you have questions about this recall. Report any health product-related side effects or complaints to Health Canada.
Recall number
81478
Official notice
2026-01-13
The hazard
The hazard
Teva Canada Limited is recalling all strengths (lots listed above) of the prescription drug Octreotide as a precautionary measure due to deficiencies in Good Manufacturing Practices (GMP) identified at its foreign manufacturing site. GMPs ensure drugs meet the appropriate quality standards for their intended use before they are sold. The deficiencies identified could lead to potential quality issues with the products, including microbiological contamination (leading to compromised sterility), contamination with foreign particles and concerns related to dosing accuracy. Potential serious health risks associated with these deficiencies include: Skin and muscle infections at the injection site, including cellulitis or abscess Severe blood infection Blood clots Hypersensitivity reactions, including life threatening allergic reactions Inflammatory reactions/lumps at the injection site Lack of therapeutic effect due to an insufficient dose Symptoms of overdose, such as hot flushes, frequent urination, fatigue, depression, anxiety and lack of concentration, or worsened side effects. Teva Octreotide acetate for injectable suspension is a long-acting prescription medication used to treat certain hormone-related disorders, including acromegaly (a condition caused by too much growth hormone), as well as severe diarrhea and flushing caused by certain tumors. Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventive actions. The Department will inform the public if any new health risks are identified.
How to check if you're affected
How to check if you're affected
Compare the product name and identifiers below with the item you own. Follow the official notice if they match.
Lots
Other
Recall Numbers
Checked manually this time?
The app alerts you when a new official recall is published — no searching, no checking back.
Turn on recall alertsAffected products
Affected products
Product 1
Product 2
Product 3
Risk / hazard
Where it was sold
Where it was sold
The source does not list specific retailers. See the official notice for where affected products were sold.
Location 1
Affected area 1
Company & contacts
Company & contacts
Brand
Manufacturer
Phone
Brand: All Strengths Of Teva Octreotide For Injectable Suspension Kit With The Lot Numbers Noted Below. Contact: Teva Canada Limited by calling toll-free. Phone 1-800-268-4127.
Source & status
Source & status
Source
Tier
Category
App estimate
Recall details
Recall details
Recall number
Source tier
Documents, notices & source
See the official notice and source documents for full details.
View full official noticeWeekly recall digest
Get next week's recalls before you need them.
One email every Monday — official-source recalls for your country, and nothing else. Unsubscribe from any email.
The digest is the slow lane — one email a week. For instant, severity-gated alerts the moment a notice is published, get the app.
This recall was published 13 Jan 2026. The next one won't wait for you to search.
RecallScope watches official sources for the brands and VINs you follow, and alerts you the moment a new notice is published.
